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CH,qprnn l0
Sincc its clinical introdr"rction cisplatin has had a nrajor ir lpacl on tl.re irrprovc-
ntent ol cancer trealment. Becausc of its curative potential in a selected nunrbcr'
ol- 1umor typcs cisplatir.r has becomc one oÍ-the most widely uscd anticance r drugs.
As out l ined in the in t roducl io l l  o l ' th is  thesis  t reatmenl  wi th c isp lat in  is  aeconr-
panied by two rrajor clinical problems. pror.rounced treatr.nent associated toxicit l
ar.rcl 1l.rc developmcnt ol-rcsistance lbr this drug. Thcse laclors have stirnulutcd the
i r lprovemcr. r t  o f  thc kuowled-ee and understancl ing o l ' thc therapeut ic  and tox ic
elÏects oí- currcntly uscd cisplatin containing rcsinrcns. On thc otl.rcr hiind tire
scalch lb l  a l te lnat ivc p lat inunr  compouncls wi th a bct tcr  therapcut ic  index rvas
in i l ia ted"  as wcrc invcst igat ions for  vr 'ays to anrc l iorate associatec l  tox ic i ty .  In  th is
thesis several ol- thcsc aspects of platinurr bascd chemotherapy for paticnts rvilh
cancer are dcscribed.
E,arlicr str.rclies revealed that rcnal lr-rnction is ledr.rccd in rrahrourished non-can-
ccr paticnts. ln chapter 2 we investigated rvhether the r.rutrit ionirl stattus hacl an el'-
fect  on rcnal  Í -unct ion in ;16 pat icnts wi lh  c l isser l inatcc l  uor l -seminonratous tcst ic-
u lar  canccr  t tcated wi th coml-r inal ion chcmc'r therapy inc luding c isp lat in .  The renal
fin.rction was cxpressed as glonrerr"rlar Í l l tration rate (GFR). cÍ1èctive rcnal plas-
ua f low (ERPF).  and l i l l ra t ion l iac l ion (FF).  NLrt r i t ional  assessmcnt  of  the pa-
t icnts was pcr formed by mcans oÍ-  three uutr i t ional  pal 'antctcrs:  wcight  lor  height
indcx (WHl) ,  creat i r . r i r . re hc ig l r t  inc lcx (CHl) .  and scrur . r . r  a lburn in eonccnt lat iou
(Salb) .  The pat icnts were d iv idcd in to t ' " r 'c ' r  g oups:  groLrp I ,  pat ients wi th a suÍ ï -
c icnt  nut l i t ional  s tatus (n = 30) ,  and group 2,  pat icnts wi th an insul Ïc icnt  nutr i -
t ional slatus (u = 1(r). Belbre trcatnrent no corrclalion was founcl bet'ui 'ecr.r thc in-
d iv ic lual  nr" r t r i t ic lnal  paranteters ancl  GFR, ERPF ancl  FF respccl ive lv .  ï 'hc
mcdian GFR. ERPF and FF o l 'both group I  and group 2 d ic l  nol  c l i l fcr  s igni f i -
cantl l ' .  Althou-eh renal Í iurctit.n of t l ic totlLl uroui-r of patients was lec'lucccl us u
resul t  o l -c isp lat in .  th is  rec lLrct iorr  rvus not  in t lucncecl  b) , thc inc l iv ic lLra l  nrr t r i t ional
paramclcrs and nol  h ighcr  in  thc group wi th tn inr t ia l ly  insLr l l lc icnt  nut l i t ional
status.  I1  l r "as concludcd that  in  th is  s tuc l l ,  nutr i t ior . r i r l  s tatus und renal  l 'ur . rc t ion o1 '
pat icnts wi th c l isscminatcc l  l s t icu lar  cancer arc not  rc latcd.
Chen.rotherapy Íbl patients with scminorla has generall i i  been reservccl fol thc pa-
t ient  wl . ro prescnts wi th advanccd d iscase.  or  l i r r  thc pat icnt  who rc lapses Íb l lou-
ing pr imary ' radiothcrapy.  The scneral  t rcat lncnt  phi losophy l . ras becn to t reat
thcsc paticrrts with cornbinatiou chcr.nothcrapv ir.r a firsl.rion sin.ri lar to tl.rosc ri ' i th
mctasla l ic  non-scut inomatous tcst icu lar  cuncer.  Since st l r , 'age chcl ro lhcrapy wt th
ctoposic lc  and c isp lat in  has shown to bc c l - lèet i re in  sorr . rc  p l t icnts Ía i l ing inc luc-
t ion chentotherap)r  wi th c isp lat in .  v inblast ine.  ancl  b lcor- r r1,c in.  ouL'  may cotrc luc le
that  these combinat ion reginrcns r r l t 'not  c{ )ntp lc tc l }  cross-res is tant .  In  ordcr  to
intprovc responsc rales anci survival wc havc trcaled patients w'it l i  udvanced sent-
i t roma rv i th  ar . r  a l tcmat ing regi rnen of  c isp lat in ,  v inblast inc.  b leonryc in (PVB) and
bleomycin.  etc lposidc.  c isp lat in  (BEP).  In  chapter  3 thc resul ts  of  th is  lcg i rnen a l r '
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SuuvaRv AND coNCLUSToNS
colrrses of alternating chemotherapy PVB/BEP. Patients were classified as Stage
I IC (n=8),  I ID (n=8),  I I I  (n=13) and IV (n=4),  e ight  pat ients had pr ior  radio-
therapy. Thirty patients were evaluable for response and 33 for toxicity. During
chemotherapy three patients died. Thirteen patients (43"1') had a complete re-
sponse, 11 (51'h) had a clinical partial response (residual radiographic mass). At
a median follow-up of 28 months (range 16-88). three patients relapsed, 6-8
months from entry. After completion of therapy there were two deaths, one due
to bleomycin-pneumonitis and one not tumor or treatment related. Twenty-six of
33 (19'%) patients achieved a continnously disease free status. LeLrkocytopenia nd
thrombocytopenia of WHO grade 3/4 occr.rrred in respectively 32133 (97"1) and
20133 (61"1,) of the patients. We conclude that this alternating regimen of PVB
and BEP has a curative potential in this patient group and that this schedule
yields comparable response rates with non alternating schedules. The high inci-
dence of serious adverse events however. makes this regimen a toxic one. A less
toxic combination regimen is presently under investigation in advanced semino-
ma patients.
The majority of the patients with disseminated testicular cancer can be cured with
cisplatin-containing chemotherapy. As a consequence, the incidence of delayed
side efÍècts of this treatment has become relevant. A nr,rmber of reports appeared
concerning the long-term side effects such as hypertension, renal function distur-
bance and vessel damage after chemotherapy for testicular cancer. Ischemic car-
diovascular and cerebrovascular events have been seen after treatment with sever-
al cytostatic agents used in these patients. There might be an increased risk that
cardiovascular disease can develop later on in the presence of additional risk fac-
tors. Chapter 4 contains the results of a study with the objective to assess cardio-
vascular risk factors over time in patients who received chemotherapy for dissem-
inated testicular cancer and were apparently cured. Fifty-seven patients (median
age,28 years; range, l6 to 43 years) who received cisplatin-containing chemothe-
rapy were studied. Serum cholesterol and high-density l ipoprotein (HDL) choles-
terol levels, body mass index (BMI), blood pressure. kidney function, and hor-
monal status were monitored during follow-up after chemotherapy (median
follow-r"rp, 88 months; range, 56 to 143 months). The BMI and cholesterol values
obtained 4 to 6 years after chemotherapy were compared with values from a
sample of healthy, age-matched Dutch males; the cholesterol evel was also com-
pared with that of 3l patients treated with orchidectomy for stage I disease. The
mean cholesterol level in patients at the start of chemotherapy was 3.96t0.98
mmol/L, and increased significantly 4 to 6 years later to 6.12=1.20 mmol/L; 49 of
57 patients had an elevated low-density l ipoprotein (LDL) cholesterol, with a
mean level of 4.4l=1.05 mmol/L. Compared with a sample of healthy Dutch men.
the chemotherapy group had an elevated cholesterol level. At 4 to 6 years. the
mean HDL cholesterol was 0.76*0.l8 mmol/L and was lower compared with that
of the healthy Dutch men. The mean BMI for all patients was 2.8 '% higher than
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expected 4 to 6 years after chemotherapy, but was not higher than expected 7 to
l0 years after chemotherapy. We conclude that in addition to other known late
side effects of chemotherapy in patients with testicular cancer. hypercholesterole-
mia and overweight might represent additional risk factors for cardiovascular dis-
ease in such patients, especially in those who are younger.
The significant morbidity of treatment with cisplatin encouraged the search for
new platinum analogues with equal efÍicacy and a reduced toxicity prohle. Car-
boplatin has ernerged as the leading cisplatin analogue with reduced nephro- and
neurotoxicity but more pronounced myelotoxicity when compared with the par-
ent platinum compound cisplatin. Another platinum analogue zeniplatin was se-
lected for clinical trials because of its mild myelosuppressive Í-fects and presumed
lack ofnephrotoxicity in phase I trials. In chapter 5 results are reported ofa phase
II study with zeniplatin in patients with advanced ovarian cancer. who have been
pretreated with cis- or carboplatin based chemotherapy. Twenty five patients with
residual or recurrent ovarian calrcer wele tleated with zeniplatin 120 mg/mr (i.v.)
once every 3 weeks for a maximum of 6 cycles. Twenty-three patients were eval-
uable for response. Myelotoxicity was mild. with grade 3 leucopenia in only l4
percent of treatment cycles, and no grade 4 leucopenia in fully dosed cycles.
Thrombocytopenia was incidental. With standard antiemetics nausea and vomit-
ing were moderate. Responses were achieved in four patients, one complete and
three partial remissions. Seven patients had stable disease after six cycles of treat-
ment and 12 patients had tumor progression. At a median Íbllow-up of 12
rnonths. the median progression free survival in responding patients was II
months and the overall survival 81%, (n-redian survival not yet reached). The me-
dian overall survival of progrcssive patier.rts amounted to 9 months, indicating the
advanced stage of discase in nost patients. Renal function was monitored by iso-
tope clearance-studies. There was no significant changc in ERPF or GFR in pa-
tients who completed six cycles oÍ- trcatment. One patient with a marginal creati-
nine clearance at baseline sulfered from sudden and severe renal failure during
the Ílrst cycle. It was concluded that zeniplatin may be active in relapsing, plati-
num pretreated patients. and has no direct eÍ-fects on renal function. Despite these
findings, occasional nephrotoxicity may occur in patients with compromised kid-
ncy function, and thus l imits the application of this new platinum analogue.
Although the toxicity profi le ol carboplatin is iavorablc compared with cisplatin,
its antitumor activity does not differ significarrtly fronr the parent compound cis-
platin. so cross-resistance between the two drugs can thereÍore be anticipated.
This stimulated the identiÍ lcation of platinum compounds that show activity in
tumors that are resistant to cisplatin, in order to improve the treatment results.
In chapters 6 and 7 we describe the first clinical experience with such a new plat-
inum cornpound lobaplatin (D-19466). Preclinical data suggested that lobaplatin
is not or only partial cross-resistant in a numbcr of cisplatin resistant cancer cell
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file. In chapter 6 the results of a phase I trial with lobaplatin, administered as an
iv bolus daily for 5 days every 4 weeks, are described. Twenty-seven patients with
refractory solid tumors received 72 treatment courses. Thrombocytopenia was
dose-limiting, its degree was related with the creatinine clearance (CRCL). For
patients with a CRCL of 60-80 ml/min the maximum tolerated dose was 40
mg/m2, for patients with a CRCL of 8l-100 mlimin it was 70 m/m2, and for
patients with a CRCL > 100 ml/min it was 85 mg/m2. The percentual platelet
nadir (percentage of day I platelet count) correlated with CRCL at different dose
levels and could be described by: percentual platelet nadir = 0.16 x CRCL
(ml/min) - 11.45 x dose 1mg/m2)) + 43.38. The potential uti l i ty of this equation
was tested and found to produce a significant correlation between observed and
predicted percentual platelet nadir. No renal function impairment was observed.
Urinary excretion of platinum was estimated and revealed that 91.5% (SE t 7.9)
of the platinum dose was excreted within 4 hours after the administration. The
recommended dose of lobaplatin iv bolus daily for 5 days for phase II studies de-
pends on renal function, namely 30 mg/m2 at CRCL 60-80 ml/min; 55 mg/m2 at
CRCL 8l-100 ml/min; 70 mg/m2 at CRCL > 100 ml/min. Of interest were one
complete response and one partial response in two patients with ovarian cancer
(both pretreated with carboplatin and cisplatin). In chapter 7 a phase I trial with
lobaplatin in another regimen is reported. Lobaplatin was adminis|ered by 72
hours continuous intravenous infusion (CI), every 4 weeks. Eleven patients
enroled in this study and received a total of 30 courses lobaplatin. Thrombocy-
topenia was dose-limiting toxicity it reached WHO grade III in 3 out of 6 patients
at 45 mglm2ll2h and, WHO grade IV in 2 out of 2 patients at 60 mglm2í2h.
Leukopenia was mild, as was the nausea and vomiting. There were no signs of
renal, neuro, or ototoxicity. The recommended phase II dose for this regimen is
45 mglmzl72h every 4 weeks. One patient with ovarian cancer, pretreated with
three different platinum complexes, achieved a partial response. It is concluded
that lobaplatin is a promising new platinum analogue with predictable hemato-
logical toxicity, no signs of renal toxicity, with anti-tumor activity in both regi-
mens, and with clinical evidence that lobaplatin might be non-cross resistant with
cisplatin and carboplatin. Further studies with lobaplatin are recommended.
Another way to improve treatment results is by dose intensification. The most im-
portant and usual dose limiting toxicity of combination chemotherapy is myelo-
suppression, which limits the treatment of large groups of patients with intensive
chemotherapy without the use of supportive care measures. The recent availabil-
ity of hematopoietic growth factors for clinical use enables us to study their abil-
ity to ameliorate chemotherapy induced bone-marrow depression. A carboplatin
based chemotherapy regimen with myelosuppression as dose-limiting side effect
seems to be suitable for combination with the administration of hematopoietic
growth factors. In chapter 8 and 9 details are given of a dose-finding study with
a new hematopoietic growth factor lnterleukin-3 (rhIL-3) after combination che-
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motherapy and of the ability of rhlL-3 to influence hematopoietic recovery. rhlL-
3 is a glycoprotein with an in vitro broad spectrum of activity on hematopoiesis.
It stimulates the proliferation and differentiation of multipotent hematopoietic
stem cells, as well as the committed progenitor cells of erythroid,
granulocyte/macrophage, megakaryocyte, eosinophil, basophil, and mast cell lin-
eages in vitro. Nineteen patients who had relapsed small cell lung cancer received
rhIL-3 after their second course of chemotherapy which consisted of either
cyclophosphamide, doxorubicin, and etoposide (CDE) every 3 weeks or vincris-
tine, ifosfamide, mesna, and carboplatin (VIMP) every 4 weeks. Twenty-four
hours after the last chemotherapy dose, rhIL-3 was administered subcutaneously
(s.c.) once daily for 14 days on an outpatient basis. Escalating dosages (l - 2 - 4
- 8 - l6 p"glkglday) of rhIL-3 were tested. Hematologic effects were evaluated by
comparing blood cell recovery after chemotherapy cycle I and cycle 2 plus rhIL-
3. Adverse effects of rhIL-3 at dosages up to 8 'p"glkglday consisted mainly of low
grade fever and flu-like symptoms. At l6 pg/kg rhIL-3 headache became dose lim-
iting. Severe neutropenia after vIMP cycle 2 plus rhIL-3 was shorter in duration
than after cycle I (3 vs 7 days). At rhIL-3 dose levels 8 and 16 prg/kg hema-
tological effects in seven patients who were treated with VIMP showed a hastened
recovery of leucocyte and neutrophil counts during cycle 2 compared with cycle
I and increased monocyte and eosinophil counts in cycle 2 compared with cycle
L rhIL-3 also increased reticulocyte, and platelet counts at dose level 8 prg/kg. No
significant stimulation of basophils and lymphocytes was observed. Apart from
hematologic effects, rhIL-3 also augments the release of cytokines such as tumor
necrosis factor-alpha (TNF-cr) and Interleukin-6 (IL-6). This release of IL-6 was
followed by a subsequent acute phase response. Of interest was also the finding
that rhIL-3 lowered cholesterol evels. we conclude that rhIL-3 can be safely ad-
ministered after chemotherapy on an outpatient basis. RhIL-3 is tolerated well at
doses up to 8 prg/kg/day and is biological active in patients after myelosuppres-
sive chemotherapy.
In this thesis some experience with the use of platinum based chemotherapy at
the University Hospital Groningen is reported. Clinical studies described in this
thesis may have in some way influenced the perspective in which platinum based
chemotherapy can be viewed. The nutritional status of a patient with dissemina-
ted testicular cancer does not seem to influence renal function prior to cisplatin
combination chemotherapy nor does it influence the renal function loss due to
cisplatin treatment. The high incidence of toxicity associated with an alternating
regimen of PVB and BEP in patients with advanced seminoma makes this regi-
men of limited value in this patient group. Further treatment improvements in
patients with advanced seminoma should be made with the use of carboplatin ba-
sed regimens. Patients cured with chemotherapy from disseminated testicular can-
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these cured patients have a disturbed lipoprotein profile. Especially in younger
patients this coincided with overweight. These risk factors in combination with
other known late side effects of platinum containing chemotherapy may represent
a threat for this group of cured cancer patients. The data indicate that at this
point in time a close follow-up of long-term survivors with special attention for
cardiovascular risk factors is warranted. Further investigation is necessary to
identify underlying mechanisms of this phenomenon in order to develop possible
intervention strategies.
Further improvement of the fate of patients with cancer, requiring treatment with
chemotherapy, awaits new strategies. In the search for new cisplatin analogues
with reduced toxicity and improved activity lobaplatin appears to be a promising
drug. Lobaplatin showed activity in patients with platinum resistant tumors. In
phase II and III studies this activity should be further defined. Since the toxicity
of lobaplatin concerns primarily the bone marrow, with thrombocytopenia as
dose limiting side effect, lobaplatin seems to be an ideal candidate for high-dose
administration. The use of hematopoietic growth factors, perhaps in conjunction
with peripheral stem-cell reinfusions, might felicitate the administration of high-
dose chemotherapy. Interleukin-3 either alone or in combination with other, more
lineage-specific growth factors such as granulocyte-colony stimulating factor or
Interleukin-6, may disclose this concept of chemotherapy dose-intensification for
larger groups of patients. An adequate control of short-term toxicity of inten-
tional curative chemotherapy may become reality in the near future. An accurate
follow-up however, of successfully treated patients, with suspicion for the occur-
rence of long-term side effects should become a second nature of medical onco-
losists.
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